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Key messages
What is already known about this subject?
 ► Occupational carcinogens have been shown to 
cause a considerable disease burden at national 
and global level. The last analysis of this issue 
at the global level was for the year 2000—this 
paper provides a new analysis for 2016.
What are the new findings?
 ► The study includes considerably more risk 
factor- outcome pairs compared to most 
previous burden of disease reports.
 ► The results highlight the important role of 
asbestos, diesel engine exhaust, second- hand 
smoke and silica in terms of occupational 
cancer burden.
 ► The burden of occupational cancer has 
increased considerably over the last two and 
a half decades, particularly due to ageing, 
changes in the proportion of workers exposed 
and population increases, with rates increasing 
for some exposures and not for others.
How might this impact on policy or clinical 
practice in the foreseeable future?
 ► Results of the present study highlight the 
need for urgent interventions to alleviate the 
global burden of occupational exposure to 
carcinogens, particularly asbestos.
AbsTrACT
Objectives This study provides a detailed analysis 
of the global and regional burden of cancer due to 
occupational carcinogens from the global Burden of 
Disease 2016 study.
Methods The burden of cancer due to 14 international 
agency for research on cancer group 1 occupational 
carcinogens was estimated using the population 
attributable fraction, based on past population exposure 
prevalence and relative risks from the literature. The 
results were used to calculate attributable deaths and 
disability- adjusted life years (DalYs).
results There were an estimated 349 000 (95% 
Uncertainty interval 269 000 to 427 000) deaths and 7.2 
(5.8 to 8.6) million DalYs in 2016 due to exposure to 
the included occupational carcinogens—3.9% (3.2% to 
4.6%) of all cancer deaths and 3.4% (2.7% to 4.0%) 
of all cancer DalYs; 79% of deaths were of males and 
88% were of people aged 55 –79 years. lung cancer 
accounted for 86% of the deaths, mesothelioma for 
7.9% and laryngeal cancer for 2.1%. asbestos was 
responsible for the largest number of deaths due to 
occupational carcinogens (63%); other important risk 
factors were secondhand smoke (14%), silica (14%) and 
diesel engine exhaust (5%). The highest mortality rates 
were in high- income regions, largely due to asbestos- 
related cancers, whereas in other regions cancer deaths 
from secondhand smoke, silica and diesel engine exhaust 
were more prominent. From 1990 to 2016, there was 
a decrease in the rate for deaths (−10%) and DalYs 
(−15%) due to exposure to occupational carcinogens.
Conclusions Work- related carcinogens are responsible 
for considerable disease burden worldwide. The results 
provide guidance for prevention and control initiatives.
InTrOduCTIOn
Occupational carcinogens have been shown to 
cause a considerable disease burden at national and 
global level.1–3 The WHO Comparative Risk Assess-
ment (CRA) project (2000) was the first attempt 
to produce comprehensive global estimates of the 
nature and extent of the burden of cancer arising 
from occupational exposures. In the year 2000, 
approximately 150 000 deaths were estimated due 
to past occupational exposure to 11carcinogens 
(three cancer outcomes—lung, mesothelioma and 
leukaemia).1
The series of Global Burden of Disease (GBD) 
studies conducted by the Institute of Health 
Metrics and Evaluation commenced with a focus 
on 2010. This GBD 2010 analysis4 included 
summary results for occupational carcinogenic 
risk factors,4 and the work has been updated 
several times at national and global level.5–8 The 
purpose of this paper is to describe in more detail 
the methods and results for the occupational 
carcinogens component of the GBD study, using 
the most recent comprehensive analysis, which 
was for 2016. This analysis, which included 14 
occupational carcinogens and eight resulting 
cancers, covers many risk factor- cancer pairs 
that were not included in such global estimates 
prior to the GBD 2010 analysis. Accompanying 
papers provide an overview of all occupational 
risk factors included in the study9 and detailed 
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Table 1 Global occupation- attributable cancer deaths and DALYs by carcinogen and cancer type, 2016—number and per cent
Carcinogen deaths* % of deaths dALYs % of dALYs
Arsenic† 8073 (2053–14 628) 2.3 (0.6–4.2) 219 218 (57 757–395 480) 3.0 (0.8–5.5)
Asbestos 218 827 (165 455–274 682) 62.7 (47.4–78.8) 3 556 876 (2 657 069–4 514 222) 49.4 (36.9–62.7)
  Larynx cancer 3743 (2024–5528) 65 506 (35 042–99 124)
  Lung cancer 181 450 (128 287–236 621) 2 844 282 (1 957 872–3 803 219)
  Ovary cancer 6022 (2984–9404) 93 120 (45 796–149 948)
  Mesothelioma 27 612 (25 559–29 341) 553 967 (507 287–597 783)
Benzene‡ 1899 (596–3123) 0.5 (0.2–0.9) 83 867 (25 512–138 493) 1.2 (0.4–1.9)
Beryllium† 259 (213–312) 0.1 (0.1–0.1) 7223 (5886–8594) 0.1 (0.1–0.1)
Cadmium† 605 (504–709) 0.2 (0.1–0.2) 16 832 (14 142–19 639) 0.2 (0.2–0.3)
Chromium† 1276 (1126–1443) 0.4 (0.3–0.4) 35 452 (31 397–40 172) 0.5 (0.4–0.6)
Diesel engine exhaust† 17 500 (15 195–20 057) 5.0 (4.4–5.8) 485 693 (426 181–553 926) 6.7 (5.9–7.7)
Formaldehyde 1086 (900–1324) 0.3 (0.3–0.4) 46 932 (38 805–56 986) 0.7 (0.5–0.8)
  Leukaemia 608 (505–722) 27 914 (22 861–33 605)
  Nasopharynx cancer 478 (330–685) 19 018 (12 994–27 091)
Nickel† 8101 (1243–20 812) 2.3 (0.4–6.0) 221 352 (34 934–563 339) 3.1 (0.5–7.8)
Polycyclic aromatic hydrocarbons† 4526 (3826–5291) 1.3 (1.1–1.5) 125 779 (105 369–145 866) 1.7 (1.5–2.0)
Secondhand smoke 49 246 (25 336–80 957) 14.1 (7.3–22.2) 1 345 915 (703 984–2 186 305) 18.7 (9.8–30.4)
  Breast cancer 4864 (1195–8401) 160 494 (39 883–276 832)
  Lung cancer 44 382 (20 655–75 463) 1 185 422 (551 749–2 013 661)
Silica† 47 999 (21 235–75 452) 13.8 (6.1–21.6) 1 303 949 (576 291–2 042 004) 18.1 (8.0–28.4)
Strong inorganic- acid mists§ 3535 (1520–6491) 1.0 (0.4–1.9) 105 226 (45 836–192 418) 1.5 (0.6–2.7)
Trichloroethylene¶ 58 (13 –108) 0.0 (0.0–0.0) 1722 (379–3228) 0.0 (0.0–0.0)
Total** 348 741 (269 406–427 386) 100.0 7 199 850 (5 813 091–8 641 244) 100.0
*The numbers in brackets are 95% uncertainty intervals.
†Causes lung cancer.
‡Causes leukaemia.
§Causes laryngeal cancer.
¶ Causes kidney cancer.
**Numbers percentages add to more than 100 due to overlapping causes.
DALY, disability- adjusted life year.
information about chronic respiratory disease arising from 
non- infectious occupational airborne exposures10
MeTHOds
General Gbd methodology
The general methodology used in GBD 2016 is described else-
where,7 11 12, as is the overall approach to occupational risk 
factors.9 These methods are briefly summarised here, and more 
detailed information is provided about the occupational carcin-
ogen analysis.
The burden of occupational disease for each carcinogen- 
outcome pair was estimated using the population attributable 
fraction (PAF), that is, the proportion of deaths or disability- 
adjusted life years (DALYs) that would not have occurred if 
exposure was at the theoretical minimum risk exposure level 
(TMREL); this was then used to estimate attributable numbers 
of deaths or DALYs. The PAF requires information on the rela-
tive risk of the disease due to the exposure of interest and 
the proportion of the target population exposed. Per capita 
rates (directly standardised by age and sex) were based on 
persons aged 15 years and above. Results were calculated for 
all years from 1990 to 2016, inclusive; the 2016 findings are 
the focus of this paper. The sociodemographic index (SDI) is 
a composite indicator of development status based on total 
fertility rate, mean education for those aged 15 years and older 
and lag distributed income per capita.7 Region- specific, SDI- 
specific and global results are reported here. Country- specific 
information is available through the GBD Compare data visu-
alisation.13 Employment data came from the International 
Labour Organization (ILO) Labour Force,14 supplemented 
where necessary by subnational data sources and modelling.
Inclusion criteria
We included all International Agency for Research on Cancer 
(IARC) Group 1 (‘carcinogenic to humans’) carcinogens with 
relevant occupational exposure circumstances (as at 2014); a non- 
trivial number of cases, exposure level and proportion of persons 
exposed and available exposure data; and all associated cancer sites 
for these agents for which there was sufficient epidemiological 
evidence of a causation link (based on IARC’s assessments).
Exposure to 14 workplace carcinogens was included and 
linked to 8 cancer primary sites—breast (secondhand smoke 
(SHS: from tobacco smoking)), kidney (trichloroethylene), 
tracheal, bronchus and lung (‘lung’) (arsenic, asbestos, beryl-
lium, cadmium, chromium VI, diesel engine exhaust, SHS, 
nickel, polycyclic aromatic hydrocarbons (PAHs), silica), larynx 
(asbestos, strong inorganic- acid mists), leukaemia (benzene, 
formaldehyde), mesothelioma (asbestos), nasopharynx (form-
aldehyde) and ovary (asbestos). With the exception of SHS and 
breast cancer (included as a pair in all GBD SHS burden esti-
mates), selection of exposure- cancer pairs for inclusion was 
based on information in IARC Monographs 1–10615.
exposure
The exposure information was based primarily on the 
CAREX (Carcinogen Exposure) database, which provided a 
point estimate of industry- specific total prevalence of expo-
sure to various carcinogens in countries of Western Europe 
153GBD 2016 Occupational Carcinogens Collaborators. Occup Environ Med 2020;77:151–159. doi:10.1136/oemed-2019-106012
Workplace
Table 2 Global occupation- attributable cancer deaths, DALYs and PAFs by cancer type and carcinogen, 2016—number and per cent
Cancer type
deaths* dALYs
n % of deaths PAF n % of dALYs PAF
Breast cancer† 4864 (1195–8401) 1.4 (0.3–2.4) 0.9 (0.2–1.6) 160 494 (39 883–276 832) 2.2 (0.6–3.8) 1.1 (0.3–1.9))
Kidney cancer‡ 58 (13–108) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 1722 (379–3228) 0.0 (0.0–0.0) 0.1 (0–0.1)
Larynx cancer 7213 (4437–10 462) 2.1 (1.3–3.0) 6.5 (4.1–9.5) 169 127 (100 947–257 618) 2.3 (1.4–3.6) 6.2 (3.7–9.4)
  Asbestos 3743 65 507
  Strong inorganic- acid mists 3535 105 226
Leukaemia 2495 (1181–3734) 0.7 (0.3–1.1) 0.8 (0.4–1.2) 111 195 (52 577–166 086) 1.5 (0.7–2.3) 1.1 (0.5–1.6)
  Benzene 1899 83 867
  Formaldehyde 608 27 914
Lung cancer 299 998 (233 708–365 251) 86.0 (67.0–100.0) 17.6 (13.8–21.3) 6 091 207 (4 777 678–7 493 601) 84.6 (66.4–100.0) 16.7 (13.1–20.5)
  Arsenic 8073 219 218
  Asbestos 181 450 2 844 282
  Beryllium 259 7223
  Cadmium 605 16 832
  Chromium 1276 35 452
  Diesel engine exhaust 17 500 485 693
  Nickel 8101 221 352
  Polycyclic aromatic hydrocarbons 4526 125 779
  Secondhand smoke 44 382 1 185 421
  Silica 47 999 1 303 949
Mesothelioma§ 27 612 (25 559–29 341) 7.9 (7.3–8.4) 91.4 (89.2–93.2) 553 967 (507 287–597 783) 7.7 (7.0–8.3) 83.8 (80.3–86.9)
Nasopharynx cancer¶ 448 (330–685) 0.1 (0.1–0.2) 0.8 (0.5–1.1) 19 018 (12 994–27 091) 0.3 (0.2–0.4) 1.0 (0.7–1.4)
Ovary cancer§ 6022 (2984–9404) 1.7 (0.9–2.7) 3.7 (1.8–5.7) 93 120 (45 796–149 948) 1.3 (0.6–2.1) 2.2 (1.0–3.5)
Total 348 741 (269 406–427 386) 100.0 3.9 (3.2–4.6) 7 199 850 (5 813 091–8 641 244) 100.0 3.4 (2.7–4.0)
*The numbers in brackets are 95% uncertainty intervals.
†Caused by second- hand smoke.
‡Caused by trichloroethylene.
§Caused by asbestos.
¶Caused by formaldehyde.
DALY, disability- adjusted life year; PAF, population- attributable fraction.
from 1990 to 1993.16 We have assumed these circumstances 
not to have changed over the time period considered here. 
CAREX does not provide separate estimates by sex, age or 
non- Western European countries; thus, for a given industry, 
the same proportions were used across all these factors (online 
supplementary table S1). These proportions were distributed 
between ‘high’ and ‘low’ exposure based on information 
about exposure prevalence in high- income countries (coun-
tries in the Australasia, high- income North America, Western 
Europe and high- income Asia Pacific regions) and low- income 
and middle- income (LMI) countries (all other countries) from 
identified relevant cohort studies. On the basis of this infor-
mation, the high to low CAREX exposure prevalence ratio was 
assumed to be 10:90 in high- income countries and 50:50 in 
LMI countries. This is considered in more detail in the online 
supplementary material.
To estimate age- specific numbers ever exposed during the 
risk exposure period, allowance was made for latency of the 
cancers and for workers who were no longer employed in an 
industry to still be at risk. To accomplish this, occupational 
turnover estimates (OTs) based on a risk exposure period 
defined by cancer latency (10–50 years for solid tumours 
(1966–2006), 0–20 years for haematopoietic cancers (1996–
2016)), annual worker turnover estimates and normal life 
expectancy were developed and applied to the original prev-
alence data.17 Separate estimates are provided for men and 
for women, for the solid tumours (long latency) and haema-
topoietic (short latency) cancers, for 2016. Separate life tables 
(based on a representative country in each region) were used to 
estimate the OTs by region. The age assumptions and regional 
life expectancies determined the age distribution of the final 
exposed population. This is described in more detail in online 
supplementary material, appendices 1 and 2.
Asbestos exposure
To estimate the proportion ever exposed to asbestos, an asbestos 
impact ratio (AIR) approach (analogous to the smoking impact 
ratio approach described elsewhere18 was used in which rates of 
malignant mesothelioma were employed as a marker of asbestos 
exposure.
The AIR is defined as the excess deaths due to mesothelioma 
observed in that population divided by the excess deaths in 
a hypothetical population that is heavily exposed to asbestos 
and gives a measurement of the exposure level of a population 
to asbestos. We then used the AIR (as the estimate of exposure 
prevalence) and relative risks to calculate the PAF for each 
cause related to asbestos. Formally, the AIR is defined as:
 
AIR = CLC−NLCC∗LC−NLC  
where, for each country- sex group:
 CLC = mesothelioma mortality rate in the study population.
 NLC = mesothelioma mortality rate in a population not 
exposed to asbestos
 C∗LC = mesothelioma mortality rate in a population highly 
exposed to asbestos
Mortality rates for mesothelioma, CLC, by country, age and 
sex, were generated by causes of death models for GBD 2016.11 
The background mortality of mesothelioma, NLC, was estimated 
using the model by Lin et al,19 which modelled mesothelioma rate 
against asbestos consumption. Using the uncertainty around the 
coefficients, we created 1000 draws of the mortality due to meso-
thelioma if there was no asbestos consumption in a country. The 
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Figure 1 Occupation- attributable cancer deaths by region, 2016 (per 100 000 persons). age- standardised; sDi=sociodemographic index.
mean value for background mortality is 0.73 and 0.47 deaths per 
million males and females, respectively. We obtained the mortality 
rate for highly exposed individuals from asbestos workers, C*LC, 
from the meta- analysis by Goodman and colleagues.20 We used 
all studies in the meta- analysis that reported both the number of 
person- years followed and the number of cases of mesothelioma 
and found the death rate of all individuals included in the studies. 
The mesothelioma death rate for highly exposed individuals was 
estimated as 226 per million people. The AIR was used to calculate 
the exposure prevalence used for estimates of lung, ovarian and 
larynx cancer due to occupational exposure to asbestos. Custom 
PAFs were calculated for occupational causes of mesothelioma in 
the population of interest by using the ratio of excess mesothe-
lioma mortality (CLC - NLC) in that population compared with the 
overall mesothelioma mortality rate (CLC) in that population.
relative risks
The relative risk estimates were primarily obtained from 
published meta- analyses or pooled studies or, where these did 
not exist, key single studies were used. Where single studies were 
used, the chosen study was the best- quality study with exposure 
circumstances that were assessed as most closely matching those 
assumed in the GBD study. The relative risks used in the analysis 
were chosen as much as possible to match an average ‘high’ expo-
sure circumstance and ‘low’ exposure circumstance, assuming 
similarity of durations and intensities of exposure between the 
source data populations and world/national populations. For 
most exposures, appropriate low- level relative risks were not 
identifiable from the literature and in these cases were set to 
one. For all but one exposure- outcome pair, the same relative 
risk estimates were used for males and females and for all age 
groups (online supplementary table S2). For lung cancer arising 
from exposure to asbestos, separate relative risks were calculated 
for males and females based on estimates of cumulative exposure 
(as described in the online supplementary material). For non- 
asbestos exposures, relative risks (RRs) were set to 1.0 for ages 
80 and over. The TMREL for each carcinogen- specific analysis 
was no exposure above background.
Population attributable fraction
PAFs for all carcinogens except asbestos were estimated for 
each age- sex- country group using the equation based on 
Levin:21
 
PAF =
∑n
x=1 RR
(
x
)
P
(
x
)−1∑n
x=1 RR
(
x
)
P
(
x
)
 
where P(x) is the proportion of persons exposed at level x 
in the relevant population and RR(x) is the relative risk corre-
sponding to exposure level x. For asbestos- related cancer, the 
above formula was used, substituting AIR for P(x).
Unless otherwise indicated, the PAFs presented in this paper 
are based on deaths.
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Figure 2 Occupational asbestos- related cancer deaths by region, 2016 (per 100 000 persons). The black bars highlight the high- income regions. age- 
standardised; sDi=sociodemographic index.
Modelling and calculation of uncertainty
The overall methodological approach and modelling used in the 
analyses, and the calculation and use of 95% uncertainty inter-
vals (95% UI), were as described elsewhere.7 9 UIs are primarily 
presented in detail in the tables to assist with the flow of the text.
resuLTs
deaths
There were estimated to be 349 000 (95% UI 282 000 to 414 000) 
cancer deaths (3.9% of all cancer deaths; 79% male) in 2016 
attributable to exposure to the occupational carcinogens evaluated. 
The deaths occurred primarily at older ages, with 88% occurring 
in people aged 55 years or older. Males had four times the rates 
of death compared with females, and the rates increased markedly 
with increasing age (online supplementary figure S1A).
The risk factors responsible for the highest proportion of 
deaths were asbestos (219 000 deaths; 62.7%), SHS (49 200; 
14.1%), silica (48 000; 13.8%) and diesel engine exhaust (17 
500; 5.0%) (table 1).
The most common cancer primary sites were lung (300 000; 
86.0%; due mainly to asbestos, diesel engine exhaust, silica, 
SHS, nickel and arsenic), mesothelioma (27 600; 7.9%; due to 
asbestos) and larynx (7200; 2.1%; due to asbestos and strong 
inorganic- acid mists) (table 2).
The greatest number of deaths occurred in the Western Europe 
(92 400; 26.5%), East Asia (80 300; 23.0%) and high- income 
North America (56 200; 16.1%) regions. The highest per capita 
rates of death were in Western Europe, Australasia, high- income 
North America and high- income Asia Pacific (essentially the high 
SDI regions and largely due to asbestos- related cancers), and the 
lowest rates were in Western, Central and Eastern sub- Saharan 
Africa(part of the low- SDI quintile) (figure 1).
dALYs
There were about 7.2 (95% UI 5.8 to 8.6) million DALYs in 
2016 from exposure to occupational carcinogens, with the 
DALYs primarily driven by Years of Life Lost (due to prema-
ture deaths). The results for DALYs were qualitatively similar 
to those for deaths–77% occurring from male illness, rates 
being much higher in males and the rate increasing in older 
persons (although for DALYs the peak was at a slightly younger 
age than was the case for deaths) (online supplementary figure 
S1B); asbestos, SHS and silica being most commonly the caus-
ative risk factor (table 1); lung cancer and mesothelioma being 
the cancers most commonly caused (table 2) and East Asia and 
Western Europe being the regions with the largest number 
of DALYs. The regions with the highest rates were essen-
tially the high SDI regions—Western Europe, Australasia and 
high- income North America and the lowest rates were again 
in Western, Eastern and Central sub- Saharan Africa (online 
supplementary figure S2).
Asbestos
Asbestos was the predominant carcinogen in terms of burden. 
The different patterns of use of asbestos are clearly reflected 
in the dominance of asbestos- related cancers in high- income 
regions, where asbestos use peaked three to four decades ago, 
in contrast to many of the LMI regions, where use became 
more common recently and is continuing.22 23 Asbestos- related 
cancers were responsible for 78%–88% of all occupational 
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Table 3 Change in global occupation- attributable deaths due to carcinogens, 1990 and 2016, number and rate (per 100 000 persons), by 
carcinogen and cancer type
Carcinogen
deaths* deaths per 100 000 persons
1990 2016 % change 1990 2016 % change
Arsenic 4829 (883–9261) 8073 (2053–14 628) 67 0.3 (0.1– 0.6) 0.3 (0.1–0.5) −2
Asbestos 145 235 (105 965–186 352 218 827 (165 455–274 682) 51 10.1 (7.4–12.9) 8.7 (6.6–10.9) −14
Benzene 1177 (394–1920) 1899 (596–3123) 61 0.1 (0.0–0.1) 0.1 (0.0–0.1) 3
Beryllium 125 (102–150) 259 (213–312) 107 0.0 (0.0–0.0) 0.0 (0.0–0.0) 22
Cadmium 284 (237–333) 605 (504–709) 133 0.0 (0.0–0.0) 0.0 (0.0–0.0) 25
Chromium 578 (508–646) 1276 (1126–1443) 121 0.0 (0.0–0.0) 0.0 (0.0 0.1) 30
Diesel engine exhaust 7981 (6981–9119) 17 500 (15 195–20 057) 119 0.5 (0.4–0.6) 0.7 (0.6–0.7) 29
Formaldehyde 678 (562–818) 1086 (900–1324) 60 0.0 (0.0–0.0) 0.0 (0.0–0.0) 1
Nickel 4946 (563–13 968) 8101 (1243–20 812) 64 0.3 (0.0–0.9) 0.3 (0.0–0.8) −4
Polycyclic aromatic hydrocarbons 2067 (1737–2421) 4526 (3826–5291) 119 0.1 (0.1–0.2) 0.2 (0.1–0.2) 29
Secondhand smoke 30 513 (15 914–49 666) 49 246 (25 336–80 957) 61 2.0 (1.1–3.3) 1.8 (0.9–3.0) −9
Silica 30 680 (12 489–49 367) 47 999 (21 235–75 452) 56 1.9 (0.8–3.1) 1.8 (0.8–2.8) −8
Strong inorganic- acid mists 2518 (1060–4645) 3535 (1520–6491) 40 0.2 (0.1–0.3) 0.1 (0.1–0.2) −18
Trichloroethylene
 
21 (5–40) 58 (13–108) 169 0.0 (0.0 0.0) 0.0 (0.0 0.0) 58
Breast cancer 2695 (628–4698) 4864 (1195–8401) 81 0.2 (0.0–0.3) 0.2 (0.0–0.3) 2
Kidney cancer 21 (5–40) 58 (13–108) 169 0.0 (0.0–0.0) 0.0 (0.0–0.0) 58
Larynx cancer 5418 (3362–7918) 7213 (4437–10 462) 33 0.4 (0.2–0.5) 0.3 (0.2–0.4) −24
Leukaemia 1551 (775–2300) 2495 (1181–3734) 61 0.1 (0.0–0.1) 0.1 (0.0–0.1) 3
Lung cancer 193 015 (150 197–237 598) 299 998 (233 708–365 251) 55 13.0 (10.2–16.0) 11.6 (9.1–14.2) −11
Mesothelioma 15 206 (13 791–17 246) 27 612 (25 559–29 341) 82 1.0 (0.9–1.2) 1.1 (1.0–1.1) 4
Nasopharynx cancer 298 (209–410) 478 (330–685) 60 0.0 (0.0–0.0) 0.0 (0.0–0.0) −2
Ovarian cancer 3845 (1905–6040) 6022 (2984–9404) 57 0.5 (0.2–0.7) 0.4 (0.2–0.7) −10
All 222 049 (178 784–268 582) 348 741 (282 253–414 071) 57 15.0 (12.1–18.1) 13.5 (11.0–16.0) −10
*The numbers in brackets are 95% uncertainty intervals.
cancer deaths in the four high- income regions and 86% in 
Southern sub- Saharan Africa, compared to an average for all 
other regions of 48% (online supplementary table S3). These 
differences were even more evident when deaths were exam-
ined on a per capita basis, with high- income countries having 
by far the highest rates of asbestos- related cancer and the rates 
in Australasia and Western Europe being about 10 times the 
average rate in the remaining regions (figure 2). In the LMI 
countries, deaths from SHS, silica and diesel engine exhaust 
were consequently more prominent than asbestos- related 
deaths. A similar pattern was seen with DALYs.
Population attributable fractions
The overall PAF for occupational carcinogens was 3.9% for 
deaths (3.4%for DALYs). This was higher for males (5.3%) 
than females (2.0%). The PAF increased with age up to age 
75–79 years. The highest PAFs were for mesothelioma (91%), 
lung cancer (18%) and laryngeal cancer (6.5%) (table 2). The 
overall PAF varied considerably between regions, from lows of 
0.7% in Western sub- Saharan Africa and 0.8% in Eastern sub- 
Saharan Africa, to highs of 8.9% in Australasia and 8.0% in 
Western Europe.
Changes over time
There were 57% more deaths and 46% more DALYs due to 
occupational carcinogens in 2016 compared to 1990. There was 
a decrease in the rate for deaths (−10%) and DALYs (−15%). 
The changes varied widely across regions, with the rate of death 
in some regions (high- income Asia Pacific, South Asia and East 
Asia) increasing by 40%–60% over 26 years, and the rate in 
other regions (Eastern Europe, Central Asia and Andean Latin 
America) falling by 30%–40% over the same period (online 
supplementary table S4).
There was an increase over time in attributable deaths and 
DALYs arising from nearly all carcinogenic risk factors. The 
relevant rates increased for some risk factors (about 30% 
for chromium, diesel engine exhaust and PAHs), decreased 
for some (18% for strong inorganic- acid mists and 14% for 
asbestos) and showed little change for others. In terms of indi-
vidual cancer primary sites(excluding kidney cancer due to 
very low numbers), the increase in deaths ranged from 33% 
for laryngeal cancer to 82% for mesothelioma. The rates for 
individual cancers decreased moderately (24% for laryngeal 
cancer) or showed little change (table 3).
dIsCussIOn
This analysis has shown that occupational exposure to carcino-
gens is an important cause of death and disability across the world. 
There were an estimated 349 000 deaths and 7.2 million DALYs in 
2016 due to these exposures. All regions had considerable numbers 
of deaths and DALYs, but the relative burden varied across regions 
and ages and by sex. Key considerations regarding the study and 
its implications are presented here. These issues are considered in 
more detail in online supplementary appendix 3.
risk factors
The main risk factors responsible for the deaths were asbestos, 
SHS and silica, with lung cancer being the predominant outcome 
for each of these exposures. Overall, 14 different occupational 
carcinogens were included in the analysis. Recent work in 
several countries suggests many such exposures remain in high- 
income countries.24–28 Although there is limited information 
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about exposures in LMI countries, it is reasonable to expect that 
such exposures there would commonly be less well controlled 
and probably more prevalent due to fewer automated facilities.29
The legacy of asbestos is clear from the analysis, with an 
estimated 219 000 deaths each year from asbestos- related 
cancer (note that this does not include deaths from asbestosis). 
In high- income countries, there has been considerable effort in 
the last three decades to minimise exposure to asbestos. Unfor-
tunately, even if exposure to asbestos was to cease completely, 
deaths from asbestos- related cancers would be expected to 
continue for the next four to five decades. While asbestos 
control has improved greatly in high- income countries, there 
are still many instances of exposure,24 26 27 sometimes inad-
vertent and sometimes seemingly through poor occupational 
health and safety practices. Of even more concern is the 
continued use of asbestos, primarily in LMI countries, often 
with very poor exposure control.30 Regions such as South 
Asia and East Asia have used increasing amounts of asbestos 
in recent decades and are still using it in a variety of occupa-
tional circumstances.23 30 31 This, combined with their large 
workforces, means the identified deaths from asbestos- related 
cancers such as mesothelioma (a cancer with very long latency) 
in these regions are a forerunner of what can be expected to 
be a far higher number of deaths in the coming decades. Even 
in some high- income countries, mesothelioma incidence has 
not yet peaked (England32) or appears to have only recently 
peaked (Australia,33 Canada,34 Italy,35 Slovenia36).
Comparison with other studies
Lower estimates in the CRA 2000 study1(which estimated half 
the number of cancer deaths) and higher absolute or equiva-
lent estimates in other global or national studies2 3 34 arise from 
differences in methodologies, particularly in terms of the risk 
factors and outcomes included, the approach to estimating the 
population at risk, and the approach to estimating the preva-
lence of exposure to asbestos, all of which are considered to be 
improved in the current study compared with previous studies.
Methodological considerations and limitations
Methodological issues relevant to the overall study are considered 
in detail in the occupational risk factors overview paper.9 The main 
aspects relevant to the carcinogen analysis included the exclusion 
of some relevant IARC Group 1 exposures, for example, UV expo-
sure from sunlight (associated with skin cancers) and welding fumes 
(associated with lung cancer) as well as IARC Group 2A exposures 
(‘probably carcinogenic to humans’) and cancer sites with limited (as 
determined by IARC) epidemiological evidence of a causal connec-
tion to included exposures (the most important exclusions in terms 
of numbers of deaths are likely to be shift work, with breast cancer 
the associated outcome and occupational exposure to the ultraviolet 
component of sunlight, leading to skin cancer); probable under- 
recognition of occupational carcinogens;37 assumptions regarding 
latency, turnover and at- risk period; the reliance on the CAREX 
database for exposure prevalence estimates; the method used for 
estimation of relative risk for lung cancer from asbestos exposure; 
the potential for mismatch between the relative risk estimates used 
and the exposure circumstances to which they have been applied; 
the exclusion of people 80 years or older from the non- asbestos 
cancer estimates (which was due to an error in programming); 
suspected overall underestimation of mesothelioma occurrence but 
possible overestimation due to the assumption that all mesothelioma 
above background occurrence is a product of occupational asbestos 
exposure and not explicitly taking account of possible interactions 
between occupational and other risk factors in people exposed to 
multiple risk factors. Of the 47 occupational carcinogenic exposures 
identified in a recent article reviewing IARC Monograph classifica-
tions up to 2017,37 14 were included in this analysis. The remainder 
were excluded because of one or more of being classified as Group 1 
after 2014 (eg, welding); lack of suitable exposure data (eg, ionising 
radiation, which accounted for nine of the 47); probable insufficient 
number of cases (eg, benzidine) and insufficient exposure level and/or 
proportion of persons exposed (eg, Bis(chloromethyl)ether).
Implications of the data
The results presented here serve to emphasise the importance 
of eliminating occupational exposure to asbestos, given the 
continuing legacy of past exposure in those countries that have 
banned use and the likelihood that countries still using it will 
face the same issues in future years. They also highlight the 
need for all countries and relevant international agencies to 
work to eliminate or control occupational exposure to carcin-
ogens, which is inadequate in many LMI countries and some-
times of the order of the high exposures that were experienced 
in past decades in high income countries. Suitable approaches 
include adopting and enforcing relevant legislation; further 
development of global and regional frameworks for control 
of occupational carcinogens; strengthening exposure and 
outcome data collection and reporting at the country level and 
emphasising the importance of primary prevention.38
COnCLusIOn
Work- related carcinogens are responsible for considerable disease 
burden worldwide. Several exposures result in major burden, and 
the total burden has worsened in the last two decades, although 
it has decreased for some exposures on a per capita basis. The 
current burden largely reflects exposures from past decades, but 
there is sound evidence that many such exposures continue in 
current workplaces. The results provide guidance for prevention 
and control initiatives that are clearly needed.
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